| Immune checkpoint profiles in luminal B breast cancer (Alliance) M Anurag, M Zhu, C Huang, S Vasaikar, J Wang, J Hoog, S Burugu, ... JNCI: Journal of the National Cancer Institute 112 (7), 737-746, 2020 | 68 | 2020 |
| DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer R Matsunuma, DW Chan, BJ Kim, P Singh, A Han, AB Saltzman, C Cheng, ... Proceedings of the National Academy of Sciences 115 (51), E11978-E11987, 2018 | 44 | 2018 |
| LRRK2 mediates axon development by regulating Frizzled3 phosphorylation and growth cone–growth cone communication K Onishi, R Tian, B Feng, Y Liu, J Wang, Y Li, Y Zou Proceedings of the National Academy of Sciences 117 (30), 18037-18048, 2020 | 29 | 2020 |
| Poziotinib inhibits HER2-mutant–driven therapeutic resistance and multiorgan metastasis in breast cancer R Kalra, CH Chen, J Wang, AB Salam, LE Dobrolecki, A Lewis, C Sallas, ... Cancer Research 82 (16), 2928-2939, 2022 | 10 | 2022 |
| Kinase inhibitor pulldown assay (KiP) for clinical proteomics AB Saltzman, DW Chan, MV Holt, J Wang, EJ Jaehnig, M Anurag, P Singh, ... Clinical Proteomics 21 (1), 3, 2024 | 3 | 2024 |
| IL-27 signaling negatively regulates FcɛRI-mediated mast cell activation and allergic response X Wan, Y Zhang, H Tang, M Li, T Jiang, J He, C Bao, J Wang, Y Song, ... Journal of Leukocyte Biology 112 (3), 411-424, 2022 | 2 | 2022 |
| Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins J Wang, AB Saltzman, EJ Jaehnig, JT Lei, A Malovannaya, MV Holt, ... Cancer Research Communications 3 (8), 1551-1563, 2023 | 1 | 2023 |
| Co-expression network analysis reveals male breast cancer specific transcriptional module X Gou, J Wang, JT Lei, EJ Jaehnig, M Anurag Cancer Research 83 (7_Supplement), 1460-1460, 2023 | | 2023 |
| Abstract PD5-05: PD5-05 DAPK3 modulates migration and invasion of triple negative breast cancers J Wang, BJ Kim, M Anurag, X Yu, X Qi, J Wang, B Zhang, C Cheng, ... Cancer Research 83 (5_Supplement), PD5-05-PD5-05, 2023 | | 2023 |
| Abstract P2-13-24: Distinct HER2 allele specific therapeutic response and preclinical efficacy of poziotinib in metastatic ER+ HER2 mutant breast cancer SM Kavuri, R Kalra, CH Chen, J Wang, AB Salam, L Dobrolecki, A Lewis, ... Cancer Research 82 (4_Supplement), P2-13-24-P2-13-24, 2022 | | 2022 |
| LUZP1 is an understudied transcriptional regulator in triple negative breast cancer (TNBC) J Wang, D Chan, BJ Kim, GV Echeverria, E Jaehnig, B Zhang, MJ Ellis Cancer Research 81 (13_Supplement), 2877-2877, 2021 | | 2021 |
Matthew J. EllisPhysician Scientist, OncologistVerified email at progendis.com
